25 research outputs found
Long-term health-related quality of life in patients with β-thalassemia after unrelated hematopoietic stem cell transplantation
The application of the Hercossett-Anionic-Surfactant process to impart Shrink-Resitance to wool
The possibility of a new pre-treatment-resin shrink-resist process, based on the application
of a dispersion of Hercosett resin and an anionic surfactant to methylamine-pre-treated
wool samples, was proposed at the Fifth International Wool Textile Research Conference1.
Further studies on this topic, as well as some attempts to develop new alternative pretreatments,
such as oxidation with hydrogen peroxide or reduction with thioglycolic acid,
have opened up new possibilities for the process and are described in this lette
CONTRIBUCION AL ESTUDIO DE LAS LANAS TRATADAS CON AlLQUILAMINAS Y TEĂIDAS CON COLORANTES REACTIVOS
INFLUENCIA DE CIERTOS TRATAMIENTOS QUĂMICOS SOBRE LA CARGA ADQUIRIDA POR UN HILO DE LANA PEINADA SOMETIDO A UN ALARGAMIENTO CONSTANTE
STUDIES ON THE APPLICATION OF THE HERCOSETT-ANIONIC-SURFACTANT PROCESS TO IMPART SHRINK-RESISTANCE TO WOOL.
STUDIES ON THE APPLICATION OF THE HERCOSETT-ANIONIC-SURFACTANT PROCESS TO IMPART SHRINK-RESISTANCE TO WOO
Long-Term Health-Related Quality of Life and Clinical Outcomes in Patients with β-Thalassemia after Splenectomy
Few data are available on the efficacy and safety of splenectomy in patients with transfusion-dependent Beta-Thalassemia Major (β-TM) and on its impact on a patientâs health-related quality of life (HRQoL). We examined the long-term HRQoL of adult patients with β-TM in comparison with those treated with medical therapy by using the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). We also evaluated the safety and efficacy of splenectomy. Overall, 114 patients with a median age of 41 years (range 18â62) were enrolled in this cross-sectional study. Twenty-nine patients underwent splenectomy (25.4%) at a median age of 12 years (range 1â32). The median follow-up after splenectomy was 42 years (range 6â55). No statistically significant differences were observed in any of the scales of the SF-36 between splenectomized and not-splenectomized patients. The majority of surgical procedures (96.6%) were approached with open splenectomy. Post-splenectomy complications were reported in eight patients (27.5%): four overwhelming infections, three with pulmonary hypertension, and one with thrombosis. A significantly higher prevalence of cardiovascular comorbidities (58.6 vs. 21.2%, p p = 0.013) was observed in splenectomized patients. These patients, however, required fewer red blood cell units per month, with only 27.6% of them transfusing more than 1 unit per month, compared with 72.9% of the not-splenectomized group. Overall, our data suggest that physicians should carefully consider splenectomy as a possible treatment option in patients with β-TM
Indications and visual outcomes of intrastromal corneal ring segment implantation in a large patient series
Health-Related Quality-of-Life Profile of Pediatric Patients with β Thalassemia after Hematopoietic Stem Cell Transplantation
Matched hematopoietic stem cell transplantation (HSCT) is a feasible and curative treatment in pediatric patients with beta thalassemia major (β-TM). However, little data are available regarding patients and their parentsâ health-related quality of life (HRQoL) after the procedure. As such, we investigated the HRQoL of pediatric patients with β-TM after HSCT compared to that of patients treated with blood transfusions and iron chelation. The health-related quality of life of 43 β-TM pediatric patients and 43 parents were evaluated using the Pediatric Quality of Life Inventory (PedsQL). A total of 25 patients underwent HSCT: 15 from a sibling and 10 from an HLA-matched donor. The median follow-up time from HSCT was 5 years (range 1â13 years). The mean ages at the survey were 10.1 years (range 5â15) and 9.6 years (range 5â15) for transfused and transplanted patients, respectively. A significant reduction in HRQoL was reported in the group of transfused patients compared with that of patients transplanted in the following PedsQL domains: childrenâs and parentsâ physical functions, Î = â15.4, p = 0.009 and Î = â11.3, p = 0.002, respectively; childrenâs and parentsâ emotional functioning, Î = â15.2, p = 0.026 and Î = â15.2, p = 0.045, respectively; childâs and parentsâ school functioning, Î = â25, p = 0.005 and Î = â22.5, p = 0.011, respectively; total child and parents scores, Î = â14.5, p = 0.004 and Î = â13.2, p = 0.005, respectively. The results of a multivariable analysis showed that the HSCT procedure was significantly associated with a higher total child PedsQL score (adjusted mean difference = 15.3, p = 0.001) and a higher total parent PedsQL score (adjusted mean difference = 14.1, p = 0.006). We found no significant difference in the HRQoL measured after sibling or unrelated human leukocyte antigen (HLA)-matched HSCT. Finally, a significant positive correlation across all the PedsQL domains was found between the scores reported by the children and those reported by their parents. In conclusion, our study shows that HSCT in pediatric patients with β-TM is associated with a good overall HRQoL profile. This information further supports physicians when counseling patients and their parents before the HSCT procedure
L'attuazione del piano decennale per l'edilizia residenziale in Piemonte : analisi di una politica pubblica
Quaderni di ricerca Ires ; n.6